Novartis’ kidney disease drug Fabhalta receives US FDA approval
Fabhalta specifically targets the alternative complement pathway of the immune system. When overly activated in the kidneys, the…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
IgAN
IGNAZ trial interim results highlight HI-Bio’s potential to differentiate in IgAN space: GlobalData
According to the results, the use of MOR-202 (felzartamab) demonstrated a deep and durable reduction in proteinuria in patients…